

Estrogen-only Menopausal Therapy

References to Supplementary Web Tables, Section 2

- Anderson GL, Limacher M, Assaf AR *et al.*; Women's Health Initiative Steering Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA*, 291:1701–1712.[doi:10.1001/jama.291.14.1701](https://doi.org/10.1001/jama.291.14.1701) PMID:15082697
- Bakken K, Alsaker E, Eggen AE, Lund E (2004). Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. *Int J Cancer*, 112:130–134.[doi:10.1002/ijc.20389](https://doi.org/10.1002/ijc.20389) PMID:15305384
- Beard CM, Hartmann LC, Keeney GL *et al.* (2000). Endometrial cancer in Olmsted County, MN: trends in incidence, risk factors and survival. *Ann Epidemiol*, 10:97–105.[doi:10.1016/S1047-2797\(99\)00039-3](https://doi.org/10.1016/S1047-2797(99)00039-3) PMID:10691063
- Beral V, Banks E, Reeves G, Bull D; Million Women Study Collaborators (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet*, 362:1330–1331.[doi:10.1016/S0140-6736\(03\)14596-5](https://doi.org/10.1016/S0140-6736(03)14596-5) PMID:12927427
- Beral V, Bull D, Green J, Reeves G; Million Women Study Collaborators (2007). Ovarian cancer and hormone replacement therapy in the Million Women Study. *Lancet*, 369:1703–1710.[doi:10.1016/S0140-6736\(07\)60534-0](https://doi.org/10.1016/S0140-6736(07)60534-0) PMID:17512855
- Beral V, Bull D, Reeves G; Million Women Study Collaborators (2005). Endometrial cancer and hormone-replacement therapy in the Million Women Study. *Lancet*, 365:1543–1551.[doi:10.1016/S0140-6736\(05\)66455-0](https://doi.org/10.1016/S0140-6736(05)66455-0) PMID:15866308
- Brinton LA, Brogan DR, Coates RJ *et al.* (1998). Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. *Menopause*, 5:145–151. PMID:9774759
- Cantwell MM, Lacey JV Jr, Schairer C *et al.* (2006). Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. *Int J Cancer*, 119:2398–2401.[doi:10.1002/ijc.22175](https://doi.org/10.1002/ijc.22175) PMID:16894568
- Chen CL, Weiss NS, Newcomb P *et al.* (2002). Hormone replacement therapy in relation to breast cancer. *JAMA*, 287:734–741.[doi:10.1001/jama.287.6.734](https://doi.org/10.1001/jama.287.6.734) PMID:11851540
- Colditz GA, Rosner B (2000). Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. *Am J Epidemiol*, 152:950–964.[doi:10.1093/aje/152.10.950](https://doi.org/10.1093/aje/152.10.950) PMID:11092437
- Daling JR, Malone KE, Doody DR *et al.* (2002). Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. *Cancer*, 95:2455–2464.[doi:10.1002/cncr.10984](https://doi.org/10.1002/cncr.10984) PMID:12467057
- Ewertz M, Møller M, Poulsen AH *et al.* (2005). Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. *Br J Cancer*, 92:1293–1297.[doi:10.1038/sj.bjc.6602472](https://doi.org/10.1038/sj.bjc.6602472) PMID:15785751
- Folsom AR, Anderson JP, Ross JA (2004). Estrogen replacement therapy and ovarian cancer. *Epidemiology*, 15:100–104.[doi:10.1097/01.ede.0000091606.31903.8e](https://doi.org/10.1097/01.ede.0000091606.31903.8e) PMID:14712153
- Fournier A, Berrino F, Riboli E *et al.* (2005). Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *Int J Cancer*, 114:448–454.[doi:10.1002/ijc.20710](https://doi.org/10.1002/ijc.20710) PMID:15551359
- Glud E, Kjaer SK, Thomsen BL *et al.* (2004). Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. *Arch Intern Med*, 164:2253–2259.[doi:10.1001/archinte.164.20.2253](https://doi.org/10.1001/archinte.164.20.2253) PMID:15534163
- Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI (1998). Postmenopausal estrogen use and invasive versus in situ breast cancer risk. *J Clin Epidemiol*, 51:1277–1283.[doi:10.1016/S0895-4356\(98\)00116-4](https://doi.org/10.1016/S0895-4356(98)00116-4) PMID:10086820
- Jacobs EJ, White E, Weiss NS *et al.* (1999). Hormone replacement therapy and colon cancer among members of a health maintenance organization. *Epidemiology*, 10:445–451.[doi:10.1097/00001648-199907000-00018](https://doi.org/10.1097/00001648-199907000-00018) PMID:10401882
- Kirsh V, Kreiger N (2002). Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. *Cancer Causes Control*, 13:583–590.[doi:10.1023/A:1016330024268](https://doi.org/10.1023/A:1016330024268) PMID:12195648
- Lacey JV Jr, Brinton LA, Leitzmann MF *et al.* (2006). Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. *J Natl Cancer Inst*, 98:1397–1405.[doi:10.1093/jnci/djj375](https://doi.org/10.1093/jnci/djj375) PMID:17018786
- Lacey JV Jr, Brinton LA, Lubin JH *et al.* (2005). Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. *Cancer Epidemiol Biomarkers Prev*, 14:1724–1731.[doi:10.1158/1055-9965.EPI-05-0111](https://doi.org/10.1158/1055-9965.EPI-05-0111) PMID:16030108
- Lacey JV Jr, Leitzmann MF, Chang SC *et al.* (2007). Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. *Cancer*, 109:1303–1311.[doi:10.1002/cncr.22525](https://doi.org/10.1002/cncr.22525) PMID:17315161
- Lacey JV Jr, Mink PJ, Lubin JH *et al.* (2002). Menopausal hormone replacement therapy and risk of ovarian cancer. *JAMA*, 288:334–341.[doi:10.1001/jama.288.3.334](https://doi.org/10.1001/jama.288.3.334) PMID:12117398

- Lee S, Kolonel L, Wilkens L *et al.* (2006). Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. *Int J Cancer*, 118:1285–1291.[doi:10.1002/ijc.21481](https://doi.org/10.1002/ijc.21481) [PMID:16170777](https://pubmed.ncbi.nlm.nih.gov/16170777/)
- Li CI, Daling JR, Malone KE *et al.* (2006). Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. *Cancer Epidemiol Biomarkers Prev*, 15:946–954.[doi:10.1158/1055-9965.EPI-05-0881](https://doi.org/10.1158/1055-9965.EPI-05-0881) [PMID:16702375](https://pubmed.ncbi.nlm.nih.gov/16702375/)
- Li CI, Malone KE, Porter PL *et al.* (2003). Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. *JAMA*, 289:3254–3263.[doi:10.1001/jama.289.24.3254](https://doi.org/10.1001/jama.289.24.3254) [PMID:12824206](https://pubmed.ncbi.nlm.nih.gov/12824206/)
- Li CI, Malone KE, Porter PL *et al.* (2008). Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. *Cancer Epidemiol Biomarkers Prev*, 17:43–50.[doi:10.1158/1055-9965.EPI-07-0558](https://doi.org/10.1158/1055-9965.EPI-07-0558) [PMID:18199710](https://pubmed.ncbi.nlm.nih.gov/18199710/)
- Li CI, Weiss NS, Stanford JL, Daling JR (2000). Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. *Cancer*, 88:2570–2577.[doi:10.1002/1097-0142\(20000601\)88:11<2570::AID-CNCR20>3.0.CO;2-O](https://doi.org/10.1002/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O) [PMID:10861435](https://pubmed.ncbi.nlm.nih.gov/10861435/)
- Lumachi F, Ermani M, Brandes AA *et al.* (2002). Breast cancer risk in healthy and symptomatic women: results of a multivariate analysis. A case-control study. *Biomed Pharmacother*, 56:416–420.[doi:10.1016/S0753-3322\(02\)00252-4](https://doi.org/10.1016/S0753-3322(02)00252-4) [PMID:12442915](https://pubmed.ncbi.nlm.nih.gov/12442915/)
- McGrath M, Michaud DS, De Vivo I (2006). Hormonal and reproductive factors and the risk of bladder cancer in women. *Am J Epidemiol*, 163:236–244.[doi:10.1093/aje/kwj028](https://doi.org/10.1093/aje/kwj028) [PMID:16319290](https://pubmed.ncbi.nlm.nih.gov/16319290/)
- Moorman PG, Schildkraut JM, Calingaert B *et al.* (2005). Menopausal hormones and risk of ovarian cancer. *Am J Obstet Gynecol*, 193:76–82.[doi:10.1016/j.ajog.2004.11.013](https://doi.org/10.1016/j.ajog.2004.11.013) [PMID:16021062](https://pubmed.ncbi.nlm.nih.gov/16021062/)
- Newcomb PA, Egan KM, Trentham-Dietz A *et al.* (2008). Prediagnostic use of hormone therapy and mortality after breast cancer. *Cancer Epidemiol Biomarkers Prev*, 17:864–871.[doi:10.1158/1055-9965.EPI-07-0610](https://doi.org/10.1158/1055-9965.EPI-07-0610) [PMID:18381475](https://pubmed.ncbi.nlm.nih.gov/18381475/)
- Newcomb PA, Titus-Ernstoff L, Egan KM *et al.* (2002). Postmenopausal estrogen and progestin use in relation to breast cancer risk. *Cancer Epidemiol Biomarkers Prev*, 11:593–600. [PMID:12101105](https://pubmed.ncbi.nlm.nih.gov/12101105/)
- Olsson HL, Ingvar C, Bladström A (2003). Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. *Cancer*, 97:1387–1392.[doi:10.1002/cncr.11205](https://doi.org/10.1002/cncr.11205) [PMID:12627501](https://pubmed.ncbi.nlm.nih.gov/12627501/)
- Persson I, Weiderpass E, Bergkvist L *et al.* (1999). Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. *Cancer Causes Control*, 10:253–260.[doi:10.1023/A:1008909128110](https://doi.org/10.1023/A:1008909128110) [PMID:10482483](https://pubmed.ncbi.nlm.nih.gov/10482483/)
- Pesch B, Ko Y, Brauch H *et al.* (2005). Factors modifying the association between hormone-replacement therapy and breast cancer risk. *Eur J Epidemiol*, 20:699–711.[doi:10.1007/s10654-005-0032-0](https://doi.org/10.1007/s10654-005-0032-0) [PMID:16151884](https://pubmed.ncbi.nlm.nih.gov/16151884/)
- Porch JV, Lee IM, Cook NR *et al.* (2002). Estrogen-progestin replacement therapy and breast cancer risk: the Women’s Health Study (United States). *Cancer Causes Control*, 13:847–854.[doi:10.1023/A:1020617415381](https://doi.org/10.1023/A:1020617415381) [PMID:12462550](https://pubmed.ncbi.nlm.nih.gov/12462550/)
- Prihartono N, Palmer JR, Louik C *et al.* (2000). A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. *Cancer Epidemiol Biomarkers Prev*, 9:443–447. [PMID:10794491](https://pubmed.ncbi.nlm.nih.gov/10794491/)
- Prizment AE, Anderson KE, Harlow BL, Folsom AR (2007). Reproductive risk factors for incident bladder cancer: Iowa Women’s Health Study. *Int J Cancer*, 120:1093–1098.[doi:10.1002/ijc.22418](https://doi.org/10.1002/ijc.22418) [PMID:17131327](https://pubmed.ncbi.nlm.nih.gov/17131327/)
- Purdie DM, Bain CJ, Siskind V *et al.* (1999). Hormone replacement therapy and risk of epithelial ovarian cancer. *Br J Cancer*, 81:559–563.[doi:10.1038/sj.bjc.6690731](https://doi.org/10.1038/sj.bjc.6690731) [PMID:10507786](https://pubmed.ncbi.nlm.nih.gov/10507786/)
- Riman T, Dickman PW, Nilsson S *et al.* (2001). Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. *Gynecol Oncol*, 83:575–585.[doi:10.1006/gyno.2001.6451](https://doi.org/10.1006/gyno.2001.6451) [PMID:11733975](https://pubmed.ncbi.nlm.nih.gov/11733975/)
- Riman T, Dickman PW, Nilsson S *et al.* (2002). Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. *J Natl Cancer Inst*, 94:497–504. [PMID:11929950](https://pubmed.ncbi.nlm.nih.gov/11929950/)
- Rodriguez C, Patel AV, Calle EE *et al.* (2001). Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. *JAMA*, 285:1460–1465.[doi:10.1001/jama.285.11.1460](https://doi.org/10.1001/jama.285.11.1460) [PMID:11255422](https://pubmed.ncbi.nlm.nih.gov/11255422/)
- Rosenberg LU, Einarisdóttir K, Friman EI *et al.* (2006b). Risk factors for hormone receptor-defined breast cancer in postmenopausal women. *Cancer Epidemiol Biomarkers Prev*, 15:2482–2488.[doi:10.1158/1055-9965.EPI-06-0489](https://doi.org/10.1158/1055-9965.EPI-06-0489) [PMID:17164374](https://pubmed.ncbi.nlm.nih.gov/17164374/)
- Rosenberg LU, Granath F, Dickman PW *et al.* (2008). Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. *Breast Cancer Res*, 10:R78.[doi:10.1186/bcr2145](https://doi.org/10.1186/bcr2145) [PMID:18803850](https://pubmed.ncbi.nlm.nih.gov/18803850/)
- Rosenberg LU, Palmer JR, Wise LA, Adams-Campbell LL (2006a). A prospective study of female hormone use and breast cancer among black women. *Arch Intern Med*, 166:760–765.[doi:10.1001/archinte.166.7.760](https://doi.org/10.1001/archinte.166.7.760) [PMID:16606813](https://pubmed.ncbi.nlm.nih.gov/16606813/)
- Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000). Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. *J Natl Cancer Inst*, 92:328–332.[doi:10.1093/jnci/92.4.328](https://doi.org/10.1093/jnci/92.4.328) [PMID:10675382](https://pubmed.ncbi.nlm.nih.gov/10675382/)

- Rossing MA, Cushing-Haugen KL, Wicklund KG *et al.* (2007). Menopausal hormone therapy and risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev*, 16:2548–2556.[doi:10.1158/1055-9965.EPI-07-0550](https://doi.org/10.1158/1055-9965.EPI-07-0550) [PMID:18086757](https://pubmed.ncbi.nlm.nih.gov/18086757/)
- Schairer C, Lubin J, Troisi R *et al.* (2000). Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *JAMA*, 283:485–491.[doi:10.1001/jama.283.4.485](https://doi.org/10.1001/jama.283.4.485) [PMID:10659874](https://pubmed.ncbi.nlm.nih.gov/10659874/)
- Shields TS, Weiss NS, Voigt LF, Beresford SA (1999). The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors. *Epidemiology*, 10:733–738.[doi:10.1097/00001648-199911000-00014](https://doi.org/10.1097/00001648-199911000-00014) [PMID:10535788](https://pubmed.ncbi.nlm.nih.gov/10535788/)
- Sit AS, Modugno F, Weissfeld JL *et al.* (2002). Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. *Gynecol Oncol*, 86:118–123.[doi:10.1006/gyno.2002.6746](https://doi.org/10.1006/gyno.2002.6746) [PMID:12144815](https://pubmed.ncbi.nlm.nih.gov/12144815/)
- Sprague BL, Trentham-Dietz A, Egan KM *et al.* (2008). Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. *Am J Epidemiol*, 168:404–411.[doi:10.1093/aje/kwn143](https://doi.org/10.1093/aje/kwn143) [PMID:18552361](https://pubmed.ncbi.nlm.nih.gov/18552361/)
- Strom BL, Schinnar R, Weber AL *et al.* (2006). Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. *Am J Epidemiol*, 164:775–786.[doi:10.1093/aje/kwj316](https://doi.org/10.1093/aje/kwj316) [PMID:16997897](https://pubmed.ncbi.nlm.nih.gov/16997897/)
- Weiderpass E, Baron JA, Adami HO *et al.* (1999). Low-potency oestrogen and risk of endometrial cancer: a case-control study. *Lancet*, 353:1824–1828.[doi:10.1016/S0140-6736\(98\)10233-7](https://doi.org/10.1016/S0140-6736(98)10233-7) [PMID:10359406](https://pubmed.ncbi.nlm.nih.gov/10359406/)
- Weiss JM, Saltzman BS, Doherty JA *et al.* (2006). Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. *Am J Epidemiol*, 164:56–62.[doi:10.1093/aje/kwj152](https://doi.org/10.1093/aje/kwj152) [PMID:16675538](https://pubmed.ncbi.nlm.nih.gov/16675538/)
- Weiss LK, Burkman RT, Cushing-Haugen KL *et al.* (2002). Hormone replacement therapy regimens and breast cancer risk(1). *Obstet Gynecol*, 100:1148–1158.[doi:10.1016/S0029-7844\(02\)02502-4](https://doi.org/10.1016/S0029-7844(02)02502-4) [PMID:12468157](https://pubmed.ncbi.nlm.nih.gov/12468157/)
- Wu AH, Yu MC, Tseng CC, Pike MC (2007). Body size, hormone therapy and risk of breast cancer in Asian-American women. *Int J Cancer*, 120:844–852.[doi:10.1002/ijc.22387](https://doi.org/10.1002/ijc.22387) [PMID:17131315](https://pubmed.ncbi.nlm.nih.gov/17131315/)